A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders

M. Gratacòs, V. Soria, M. Urretavizcaya, J. R. González, J. M. Crespo, M. Bayés, R. de Cid, J. M. Menchón, J. Vallejo, Xavier P. Estivill

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Brain-derived neurotrophic factor (BDNF) has been studied extensively in relation to the susceptibility to mood disorders (MD), although it remains to be clarified whether BDNF is a susceptibility locus for MD phenotypes, including therapeutic response to antidepressants. We have performed a single-marker and haplotype association study of eight TagSNPs polymorphisms in the genomic region containing the BDNF gene in 342 control subjects and 374 patients with MD, and have tested the association with antidepressant treatment outcome. None of the eight single nucleotide polymorphisms (TagSNPs) was significantly associated with MD phenotype after Bonferroni correction. In the single-marker analysis, a SNP was found to be associated with the patient's state of 'remitter' after adequate trial with a single antidepressant phenotype (odds ratio (OR) = 2.95; P = 0.0025). We also identified a haplotype associated with this phenotype. This study supports the implication of BDNF in antidepressant treatment outcome in MD, with specific association with 5′ upstream region of BDNF gene.

Original languageEnglish
Pages (from-to)101-112
Number of pages12
JournalPharmacogenomics Journal
Volume8
Issue number2
DOIs
Publication statusPublished - Apr 2008
Externally publishedYes

Fingerprint

Brain-Derived Neurotrophic Factor
Mood Disorders
Haplotypes
Antidepressive Agents
Phenotype
Single Nucleotide Polymorphism
Genes
Odds Ratio

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. / Gratacòs, M.; Soria, V.; Urretavizcaya, M.; González, J. R.; Crespo, J. M.; Bayés, M.; de Cid, R.; Menchón, J. M.; Vallejo, J.; Estivill, Xavier P.

In: Pharmacogenomics Journal, Vol. 8, No. 2, 04.2008, p. 101-112.

Research output: Contribution to journalArticle

Gratacòs, M, Soria, V, Urretavizcaya, M, González, JR, Crespo, JM, Bayés, M, de Cid, R, Menchón, JM, Vallejo, J & Estivill, XP 2008, 'A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders', Pharmacogenomics Journal, vol. 8, no. 2, pp. 101-112. https://doi.org/10.1038/sj.tpj.6500460
Gratacòs, M. ; Soria, V. ; Urretavizcaya, M. ; González, J. R. ; Crespo, J. M. ; Bayés, M. ; de Cid, R. ; Menchón, J. M. ; Vallejo, J. ; Estivill, Xavier P. / A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. In: Pharmacogenomics Journal. 2008 ; Vol. 8, No. 2. pp. 101-112.
@article{55266d13ec0d41ed9a1c849ce8b39676,
title = "A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders",
abstract = "Brain-derived neurotrophic factor (BDNF) has been studied extensively in relation to the susceptibility to mood disorders (MD), although it remains to be clarified whether BDNF is a susceptibility locus for MD phenotypes, including therapeutic response to antidepressants. We have performed a single-marker and haplotype association study of eight TagSNPs polymorphisms in the genomic region containing the BDNF gene in 342 control subjects and 374 patients with MD, and have tested the association with antidepressant treatment outcome. None of the eight single nucleotide polymorphisms (TagSNPs) was significantly associated with MD phenotype after Bonferroni correction. In the single-marker analysis, a SNP was found to be associated with the patient's state of 'remitter' after adequate trial with a single antidepressant phenotype (odds ratio (OR) = 2.95; P = 0.0025). We also identified a haplotype associated with this phenotype. This study supports the implication of BDNF in antidepressant treatment outcome in MD, with specific association with 5′ upstream region of BDNF gene.",
author = "M. Gratac{\`o}s and V. Soria and M. Urretavizcaya and Gonz{\'a}lez, {J. R.} and Crespo, {J. M.} and M. Bay{\'e}s and {de Cid}, R. and Mench{\'o}n, {J. M.} and J. Vallejo and Estivill, {Xavier P.}",
year = "2008",
month = "4",
doi = "10.1038/sj.tpj.6500460",
language = "English",
volume = "8",
pages = "101--112",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders

AU - Gratacòs, M.

AU - Soria, V.

AU - Urretavizcaya, M.

AU - González, J. R.

AU - Crespo, J. M.

AU - Bayés, M.

AU - de Cid, R.

AU - Menchón, J. M.

AU - Vallejo, J.

AU - Estivill, Xavier P.

PY - 2008/4

Y1 - 2008/4

N2 - Brain-derived neurotrophic factor (BDNF) has been studied extensively in relation to the susceptibility to mood disorders (MD), although it remains to be clarified whether BDNF is a susceptibility locus for MD phenotypes, including therapeutic response to antidepressants. We have performed a single-marker and haplotype association study of eight TagSNPs polymorphisms in the genomic region containing the BDNF gene in 342 control subjects and 374 patients with MD, and have tested the association with antidepressant treatment outcome. None of the eight single nucleotide polymorphisms (TagSNPs) was significantly associated with MD phenotype after Bonferroni correction. In the single-marker analysis, a SNP was found to be associated with the patient's state of 'remitter' after adequate trial with a single antidepressant phenotype (odds ratio (OR) = 2.95; P = 0.0025). We also identified a haplotype associated with this phenotype. This study supports the implication of BDNF in antidepressant treatment outcome in MD, with specific association with 5′ upstream region of BDNF gene.

AB - Brain-derived neurotrophic factor (BDNF) has been studied extensively in relation to the susceptibility to mood disorders (MD), although it remains to be clarified whether BDNF is a susceptibility locus for MD phenotypes, including therapeutic response to antidepressants. We have performed a single-marker and haplotype association study of eight TagSNPs polymorphisms in the genomic region containing the BDNF gene in 342 control subjects and 374 patients with MD, and have tested the association with antidepressant treatment outcome. None of the eight single nucleotide polymorphisms (TagSNPs) was significantly associated with MD phenotype after Bonferroni correction. In the single-marker analysis, a SNP was found to be associated with the patient's state of 'remitter' after adequate trial with a single antidepressant phenotype (odds ratio (OR) = 2.95; P = 0.0025). We also identified a haplotype associated with this phenotype. This study supports the implication of BDNF in antidepressant treatment outcome in MD, with specific association with 5′ upstream region of BDNF gene.

UR - http://www.scopus.com/inward/record.url?scp=40949152013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949152013&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500460

DO - 10.1038/sj.tpj.6500460

M3 - Article

C2 - 17505499

AN - SCOPUS:40949152013

VL - 8

SP - 101

EP - 112

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 2

ER -